With increased R&D investment from domestic enterprises, breakthroughs have been achieved in the purity, stability, and large-scale production of new material and pharmaceutical intermediates. More and more domestic intermediate products are being exported overseas, earning consistent praise from international clients for their stable quality and high cost-performance ratio, propelling China's transition from a "major producer of intermediates" to an "industrial powerhouse."